Cargando…

STOP 301: A Phase 3, open‐label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD(®)) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients

OBJECTIVE: To report the safety, tolerability, exploratory efficacy, and patient acceptability of INP104 for the acute treatment of migraine from the Phase 3 STOP 301 trial. BACKGROUND: Dihydroergotamine (DHE) has long been used to treat migraine, but intravenous administration is invasive, frequent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Timothy R., Winner, Paul, Aurora, Sheena K., Jeleva, Maria, Hocevar‐Trnka, Jasna, Shrewsbury, Stephen B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Submissions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292844/ https://www.ncbi.nlm.nih.gov/pubmed/34363701 http://dx.doi.org/10.1111/head.14184

Ejemplares similares

A Phase 1, Randomized, Open‐Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects
por: Albrecht, Detlef, et al.
Publicado: (2020)

Delivery of Dihydroergotamine Mesylate to the Upper Nasal Space for the Acute Treatment of Migraine: Technology in Action
por: Cooper, Wade, et al.
Publicado: (2022)

Dihydroergotamine (DHE) – Then and Now: A Narrative Review
por: Silberstein, Stephen D., et al.
Publicado: (2019)

Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial
por: Ailani, Jessica, et al.
Publicado: (2020)

Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE‐1, EVOLVE‐2, and REGAIN Randomized, Double‐Blind, Placebo‐Controlled Studies
por: Nichols, Russell, et al.
Publicado: (2018)

Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials
por: Stauffer, Virginia L., et al.
Publicado: (2019)

Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies
por: Detke, Holland C., et al.
Publicado: (2019)

A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine
por: Winner, Paul K., et al.
Publicado: (2020)

Clinical Characteristics and Treatment Patterns Among Patients Diagnosed With Cluster Headache in U.S. Healthcare Claims Data
por: Choong, Casey K., et al.
Publicado: (2017)

Patient preference for early onset of efficacy of preventive migraine treatments
por: Ailani, Jessica, et al.
Publicado: (2022)

Aprepitant for the management of nausea with inpatient IV dihydroergotamine
por: Chou, Denise E., et al.
Publicado: (2016)

Disasters in Europe: Inviting authors to submit scientific and practical papers on disasters in their country
Publicado: (2000)

PDA (Prolonged Depolarizing Afterpotential) - Defective Mutants: The Story of nina's and ina's—pinta and santa maria, Too
por: Pak, William L., et al.
Publicado: (2012)

AVP-825 Breath-Powered Intranasal Delivery System Containing 22 mg Sumatriptan Powder vs 100 mg Oral Sumatriptan in the Acute Treatment of Migraines (The COMPASS Study): A Comparative Randomized Clinical Trial Across Multiple Attacks
por: Tepper, Stewart J, et al.
Publicado: (2015)

A Double-Blind, Placebo-Controlled Study of Repetitive Transnasal Sphenopalatine Ganglion Blockade With Tx360® as Acute Treatment for Chronic Migraine
por: Cady, Roger, et al.
Publicado: (2015)

A Randomized, Double-Blind, Placebo-Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder (AVP-825) in the Treatment of Acute Migraine (The TARGET Study)
por: Cady, Roger K, et al.
Publicado: (2015)

Improved Pharmacokinetics of Sumatriptan With Breath Powered™ Nasal Delivery of Sumatriptan Powder
por: Obaidi, Mohammad, et al.
Publicado: (2013)

Severe Headache or Migraine History Is Inversely Correlated With Dietary Sodium Intake: NHANES 1999–2004
por: Pogoda, Janice M., et al.
Publicado: (2016)

Kinetic Oscillation Stimulation as Treatment of Acute Migraine: A Randomized, Controlled Pilot Study
por: Juto, Jan-Erik, et al.
Publicado: (2015)

The Neuropsychology of Cluster Headache: Cognition, Mood, Disability, and Quality of Life of Patients With Chronic and Episodic Cluster Headache
por: Torkamani, Mariam, et al.
Publicado: (2015)

Real-World Economic Impact of OnabotulinumtoxinA in Patients With Chronic Migraine
por: Rothrock, John F, et al.
Publicado: (2014)

IMPROVING THE EFFECTIVENESS AND EFFICIENCY OF EVIDENCE PRODUCTION FOR HEALTH TECHNOLOGY ASSESSMENT
por: Facey, Karen, et al.
Publicado: (2015)

A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology
por: Maurea, Nicola, et al.
Publicado: (2016)

A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology
por: Spallarossa, Paolo, et al.
Publicado: (2016)

Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Dodick, David W., et al.
Publicado: (2016)

Non–Invasive Vagus Nerve Stimulation for the ACute Treatment of Cluster Headache: Findings From the Randomized, Double‐Blind, Sham‐Controlled ACT1 Study
por: Silberstein, Stephen D., et al.
Publicado: (2016)

Robotic Near-Total Pancreatectomy for Nesidioblastosis after Bariatric Surgery
por: Macedo, Antonio Luiz de Vasconcellos, et al.
Publicado: (2016)

A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache‐Related Disability
por: Lipton, Richard B., et al.
Publicado: (2016)

Screening of Two ADH4 Variations in a Swedish Cluster Headache Case–Control Material
por: Fourier, Carmen, et al.
Publicado: (2016)

A Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina
por: Depre, Christophe, et al.
Publicado: (2018)

Diuretics: A possible keystone in upholding cognitive health
por: DeLoach, Tyler, et al.
Publicado: (2018)

Evaluation of provider response to positive depression screenings and physician attitudes on integrating psychiatric pharmacist services in primary care settings
por: Denson, Brittany H., et al.
Publicado: (2018)

Outcomes of patient education practices to optimize the safe use of lithium: A literature review
por: Zolezzi, Monica, et al.
Publicado: (2018)

Mania possibly linked with bupropion for smoking cessation: A case report
por: Dwyer, Stephanie, et al.
Publicado: (2016)

Evaluation of the use of low-dose quetiapine and the risk of metabolic consequences: A retrospective review
por: Carr, Chelsea N., et al.
Publicado: (2016)

A pilot study evaluating the effectiveness of a medicines education group in a mental health inpatient setting: A UK perspective
por: White, Daniel, et al.
Publicado: (2018)

A design and focus group evaluation of dietary choices tools for an underserved population
por: McMorris, Tressa, et al.
Publicado: (2016)

A consumer-led intervention to improve pharmacists' attitudes toward mental illness
por: Rickles, Nathaniel M., et al.
Publicado: (2016)

Identification, assessment, and management of pain in patients with advanced dementia
por: Malotte, Kasey L., et al.
Publicado: (2016)

Suicide prevention in pharmaceutical education: Raising awareness with inspiring stories
por: Vincent, Philippe D., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ngsasl8rnee5t1mcadh5vvfv0v